Table 4.
Carcinogenicity and mutagenicity of AMES test and hERG inhibition prediction for the ART-THY hybrids, parental and control compounds
| Compound name | Mutagenicity (Ames test) | Carcinogenicity | hERG inhibition | |
|---|---|---|---|---|
| Mouse | Rat | |||
| Parental ligands | ||||
| ART | Mutagen | Negative | Positive | Low risk |
| ARA | Non-mutagen | Negative | Positive | Low risk |
| THY | Mutagen | Positive | Positive | Low risk |
| Artemisinin–thymoquinone hybrids | ||||
| T1 | Non-mutagen | Negative | Positive | Low risk |
| T2 | Non-mutagen | Negative | Positive | Low risk |
| T3 | Non-mutagen | Negative | Positive | Low risk |
| T4 | Non-mutagen | Negative | Positive | Low risk |
| T5 | Non-mutagen | Negative | Positive | Low risk |
| T6 | Non-mutagen | Negative | Negative | Low risk |
| T7 | Non-mutagen | Negative | Negative | Low risk |
| Control-ligands | ||||
| ANK | Mutagen | Positive | Negative | Ambiguous |
| AZT | Non-mutagen | Negative | Negative | Ambiguous |
| BRT | Mutagen | Negative | Negative | Medium risk |
| CLQ | Mutagen | Negative | Positive | Medium risk |
| RDS | Non-mutagen | Negative | Negative | Ambiguous |
AZT azithromycin, BRT baricitinib, RDS remdesivir, ANK anakinra, CLQ chloroquine, ART artemisin, ARA artemisin acid, THY thymoquinone